Replies to post #3762 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

RVNC 1Q23 financial highlights:

https://investors.revance.com/news-releases/news-release-details/revance-reports-first-quarter-2023-financial-results-provides

1Q23 Daxxify sales were $15.4M, +60% QoQ. (1Q23 was the first full quarter since Daxxify was approved by the FDA.)

1Q23 dermal-filler sales were $30.3M, -13% QoQ and +45% YoY.

Note: The first and third calendar quarters are seasonally slower than the second and fourth calendar quarters in the US aesthetics market.

1Q23 GAAP and non-GAAP operating expenses (excluding revenue and COGS) were $107.4M and $71.5M, respectively, consistent with RVNC’s prior full-year 2023 guidance of $460-480M and $320-340M.

Cash at 3/31/23 was $273.9M, a reduction of $66.8M since 12/31/22.